English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
ESG Reports
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF RESEARCH UPDATES ON KN026 AT THE SABCS 2023
2023-12-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
2023-12-05
Next Day Disclosure Return
2023-11-28
VOLUNTARY ANNOUNCEMENT - CLARIFICATION
2023-11-24
INSIDE INFORMATION ANNOUNCEMENT - PRELIMINARY RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003 IN AUSTRALIA FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS
2023-11-16
INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046 FOR THE TREATMENT OF ADVANCED PDAC
2023-11-14
VOLUNTARY ANNOUNCEMENT -UNUSUAL PRICE MOVEMENTS
2023-11-14
VOLUNTARY ANNOUNCEMENT - KN026 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA
2023-11-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
2023-11-06
GRANT OF SHARE OPTIONS
2023-10-24
5
6
7
8
9
10
11
PREV
8/27
NEXT